산업동향
The Changing Face of R&D in the Future Pharmaceutical Landscape
- 등록일2008-05-30
- 조회수6245
- 분류산업동향 > 제품 > 바이오의약
-
자료발간일
2008-04-02
-
출처
http://www.deloitte.com
-
원문링크
-
키워드
#Pharmaceutical#R&D
- 첨부파일
The Changing Face of R&D in the Future Pharmaceutical Lands...
The Changing Face of R&D in the Future Pharmaceutical Landscape
A productivity crisis is happening in the pharmaceutical research and development (R&D) industry. Technological is disrupting the status quo and will drive in all aspects of the industry, which is exhibiting several characteristics of maturing industries. The lack of results suggests that the current approach to small molecule R&D may be approaching exhaustion.
Concurrently, the industry’s operating landscape is fundamentally changing, and this will force significant s among existing pharmaceutical companies. It is anticipated that the future of the pharmaceutical industry will include New PharmCos that are explicitly configured to succeed in this new fast-paced environment. These New PharmCos will be a fundamental threat to existing players, which will need to realign their R&D methods to be able to adapt in the changing landscape. Read The Changing Face of R&D in the Future Pharmaceutical Landscape to learn more about the emerging paradigm in drug development.
Table of Contents
The Changing Face of R&D in the Future
Pharmaceutical Landscape ........................ 1
A Successful, Maturing Industry ................................................... 1
Standardized Business Model Has Emerged .................................. 1
This Business Model is Increasingly Unsatisfactory ......................... 2
A Successful, Maturing Industry ................................................... 1
Standardized Business Model Has Emerged .................................. 1
This Business Model is Increasingly Unsatisfactory ......................... 2
A Changing Landscape ................................................................. 3
A Fundamental Shift in the Industry’s Operating
Environment is Under Way ............................................................ 3
The Shift will Drive Major Changes in Existing Companies ............. 3
A Fundamental Shift in the Industry’s Operating
Environment is Under Way ............................................................ 3
The Shift will Drive Major Changes in Existing Companies ............. 3
The Future R&D Model ................................................................ 6
Signifi cant New Players ? New PharmaCos ? Will Emerge ............. 6
R&D Realignment is Needed to be Financially Successful
in the New Landscape .................................................................. 7
Industry Maturity and Rebirth ....................................................... 7
Signifi cant New Players ? New PharmaCos ? Will Emerge ............. 6
R&D Realignment is Needed to be Financially Successful
in the New Landscape .................................................................. 7
Industry Maturity and Rebirth ....................................................... 7
References ..................................................................................... 8
첨부 파일을 참고하시기 바랍니다.
관련정보
지식
동향